Congress responds to the IOM drug safety report--in full.
Psaty, Bruce M
Congress responds to the IOM drug safety report--in full. [electronic resource] - JAMA Nov 2007 - 2185-7 p. digital
Publication Type: Journal Article; Research Support, N.I.H., Extramural
1538-3598
10.1001/jama.298.18.2185 doi
Clinical Trials as Topic--legislation & jurisprudence
Conflict of Interest
Databases, Factual
Drug Approval--legislation & jurisprudence
Drug-Related Side Effects and Adverse Reactions
National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division
Politics
Product Surveillance, Postmarketing
United States
United States Food and Drug Administration
Congress responds to the IOM drug safety report--in full. [electronic resource] - JAMA Nov 2007 - 2185-7 p. digital
Publication Type: Journal Article; Research Support, N.I.H., Extramural
1538-3598
10.1001/jama.298.18.2185 doi
Clinical Trials as Topic--legislation & jurisprudence
Conflict of Interest
Databases, Factual
Drug Approval--legislation & jurisprudence
Drug-Related Side Effects and Adverse Reactions
National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division
Politics
Product Surveillance, Postmarketing
United States
United States Food and Drug Administration